secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001437749-23-027993
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics appoints Neil F. McFarlane as CEO effective Oct 10, 2023
---------------------------------------------------------------------------

- Neil F. McFarlane named President and CEO, succeeding interim CEO Christal Mickle who remains Chief Development Officer.
- McFarlane receives $700k base salary, 60% target bonus, 600k stock options, and 200k RSUs vesting over 4 years.
- Relocation assistance of $350k provided; severance includes 1x salary (1.5x upon change in control).
- Board member Joseph B. Saluri resigned effective immediately after McFarlane's appointment.
- McFarlane brings 25+ years biopharma experience, most recently CEO of Adamas Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/zvra20231005_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-027993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer